EMEA-000972-PIP01-10-M05
Key facts
| Active substance |
Laquinimod (sodium)
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0143/2017
|
| PIP number |
EMEA-000972-PIP01-10-M05
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of relapsing remitting multiple sclerosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Teva GmbH
Tel. +41 552201546 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|